Wahlster Sarah, Wijdicks Eelco F M, Patel Pratik V, Greer David M, Hemphill J Claude, Carone Marco, Mateen Farrah J
From the Department of Neurology (S.W., F.J.M.), Massachusetts General Hospital, Boston; Department of Neurology (S.W.), Brigham and Women's Hospital, Boston; Harvard Medical School (S.W., F.J.M.), Boston, MA; Division of Neurocritical Care (E.F.M.W.), Mayo Clinic, Rochester, MN; Department of Anesthesiology and Pain Medicine (P.V.P.), Harborview Medical Center, Seattle, WA; Department of Neurology (D.M.G.), Yale University School of Medicine, New Haven, CT; Department of Neurology (J.C.H.), San Francisco General Hospital, CA; and Department of Biostatistics (M.C.), University of Washington, Seattle.
Neurology. 2015 May 5;84(18):1870-9. doi: 10.1212/WNL.0000000000001540. Epub 2015 Apr 8.
To assess the practices and perceptions of brain death determination worldwide and analyze the extent and nature of variations among countries.
An electronic survey was distributed globally to physicians with expertise in neurocritical care, neurology, or related disciplines who would encounter patients at risk of brain death.
Most countries (n = 91, response rate 76%) reported a legal provision (n = 63, 70%) and an institutional protocol (n = 70, 77%) for brain death. Institutional protocols were less common in lower-income countries (2/9 of low [22%], 9/18 lower-middle [50%], 22/26 upper-middle [85%], and 37/38 high-income countries [97%], p < 0.001). Countries with an organized transplant network were more likely to have a brain death provision compared with countries without one (53/64 [83%] vs 6/25 [24%], p < 0.001). Among institutions with a formalized brain death protocol, marked variability occurred in requisite examination findings (n = 37, 53% of respondents deviated from the American Academy of Neurology criteria), apnea testing, necessity and type of ancillary testing (most commonly required test: EEG [n = 37, 53%]), time to declaration, number and qualifications of physicians present, and criteria in children (distinct pediatric criteria: n = 38, 56%).
Substantial differences in perceptions and practices of brain death exist worldwide. The identification of discrepancies, improvement of gaps in medical education, and formalization of protocols in lower-income countries provide first pragmatic steps to reconciling these variations. Whether a harmonized, uniform standard for brain death worldwide can be achieved remains questionable.
评估全球脑死亡判定的实践情况与认知,并分析各国之间差异的程度与性质。
在全球范围内向具有神经重症监护、神经病学或相关学科专业知识且会接触到脑死亡风险患者的医生进行电子调查。
大多数国家(n = 91,回复率76%)报告有脑死亡的法律规定(n = 63,70%)和机构方案(n = 70,77%)。机构方案在低收入国家不太常见(低收入国家2/9 [22%],中低收入国家9/18 [50%],中高收入国家22/26 [85%],高收入国家37/38 [97%],p < 0.001)。与没有组织化移植网络的国家相比,有组织化移植网络的国家更有可能有脑死亡规定(53/64 [83%] 对6/25 [24%],p < 0.001)。在有正式脑死亡方案的机构中,必要的检查结果(n = 37,53%的受访者偏离了美国神经病学学会标准)、呼吸暂停测试、辅助测试的必要性和类型(最常要求的测试:脑电图 [n = 37,53%])、宣布脑死亡的时间、在场医生的数量和资质以及儿童标准(不同的儿科标准:n = 38,56%)存在显著差异。
全球在脑死亡的认知和实践方面存在重大差异。识别差异、改善医学教育中的差距以及在低收入国家使方案正式化是协调这些差异的首要务实步骤。全球是否能够实现统一的脑死亡标准仍值得怀疑。